INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29901, 19368, 'Urofollitropin', 'Thromboembolism', 'Thromboembolic events, including venous thrombophlebitis, pulmonary embolism, pulmonary infarction, cerebrovascular occlusion (stroke), and arterial occlusion resulting in loss of limb, have been reported during administration of gonadotropin therapy, both in association with and independent of the Ovarian Hyperstimulation Syndrome.  Therapy with gonadotropins should be administered cautiously to patients with or predisposed to thromboembolism.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29902, 22671, 'Urofollitropin', 'Thromboembolism', 'Thromboembolic events, including venous thrombophlebitis, pulmonary embolism, pulmonary infarction, cerebrovascular occlusion (stroke), and arterial occlusion resulting in loss of limb, have been reported during administration of gonadotropin therapy, both in association with and independent of the Ovarian Hyperstimulation Syndrome.  Therapy with gonadotropins should be administered cautiously to patients with or predisposed to thromboembolism.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29903, 15466, 'Urofollitropin', 'Brain Neoplasms', 'The use of urofollitropin is contraindicated in the presence of any intracranial lesion or tumor.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29904, 19367, 'Urofollitropin', 'Brain Neoplasms', 'The use of urofollitropin is contraindicated in the presence of any intracranial lesion or tumor.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29905, 19368, 'Urofollitropin', 'Brain Neoplasms', 'The use of urofollitropin is contraindicated in the presence of any intracranial lesion or tumor.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29906, 22671, 'Urofollitropin', 'Brain Neoplasms', 'The use of urofollitropin is contraindicated in the presence of any intracranial lesion or tumor.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29907, 15466, 'Urofollitropin', 'Lung Diseases', 'Serious pulmonary conditions such as atelectasis, acute respiratory syndrome, and exacerbation of asthma have been reported in women treated with gonadotropins.  Caution and monitoring is advised if used in women with pulmonary conditions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29908, 19367, 'Urofollitropin', 'Lung Diseases', 'Serious pulmonary conditions such as atelectasis, acute respiratory syndrome, and exacerbation of asthma have been reported in women treated with gonadotropins.  Caution and monitoring is advised if used in women with pulmonary conditions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29909, 19368, 'Urofollitropin', 'Lung Diseases', 'Serious pulmonary conditions such as atelectasis, acute respiratory syndrome, and exacerbation of asthma have been reported in women treated with gonadotropins.  Caution and monitoring is advised if used in women with pulmonary conditions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29910, 22671, 'Urofollitropin', 'Lung Diseases', 'Serious pulmonary conditions such as atelectasis, acute respiratory syndrome, and exacerbation of asthma have been reported in women treated with gonadotropins.  Caution and monitoring is advised if used in women with pulmonary conditions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29911, 14157, 'Urokinase', 'Hemorrhagic Disorders', 'The use of thrombolytics is contraindicated in patients with an active bleed (internal), trauma/surgery (recent CPR/intracranial/intraspinal surgery within 2 months), bleeding diathesis, history of cerebrovascular (CV) accident, intracranial defect (aneurysm, arteriovenous malformation, neoplasm), or severe uncontrolled arterial hypertension (SBP>180/DBP>110).  Risk versus benefit should be carefully considered in the following conditions and thrombolytic therapy administered with caution in patients with recent (10 days) serious GI bleed or recent (10 days) surgical procedure (coronary bypass graft, obstetrical delivery, organ biopsy, puncture of noncompressible vessel), left heart thrombus, subacute bacterial endocarditis, hemostatic defect, CV disease, diabetic hemorrhagic retinopathy, or pregnancy.  Clinical monitoring of hematopoietic, bleeding and coagulation functions is recommended prior to initiation of thrombolytic therapy.  Measures of fibrinolytic activity and/or coagulation functions during infusion do not correlate with efficacy or risk of bleeding.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29912, 14158, 'Urokinase', 'Hemorrhagic Disorders', 'The use of thrombolytics is contraindicated in patients with an active bleed (internal), trauma/surgery (recent CPR/intracranial/intraspinal surgery within 2 months), bleeding diathesis, history of cerebrovascular (CV) accident, intracranial defect (aneurysm, arteriovenous malformation, neoplasm), or severe uncontrolled arterial hypertension (SBP>180/DBP>110).  Risk versus benefit should be carefully considered in the following conditions and thrombolytic therapy administered with caution in patients with recent (10 days) serious GI bleed or recent (10 days) surgical procedure (coronary bypass graft, obstetrical delivery, organ biopsy, puncture of noncompressible vessel), left heart thrombus, subacute bacterial endocarditis, hemostatic defect, CV disease, diabetic hemorrhagic retinopathy, or pregnancy.  Clinical monitoring of hematopoietic, bleeding and coagulation functions is recommended prior to initiation of thrombolytic therapy.  Measures of fibrinolytic activity and/or coagulation functions during infusion do not correlate with efficacy or risk of bleeding.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29913, 14159, 'Urokinase', 'Hemorrhagic Disorders', 'The use of thrombolytics is contraindicated in patients with an active bleed (internal), trauma/surgery (recent CPR/intracranial/intraspinal surgery within 2 months), bleeding diathesis, history of cerebrovascular (CV) accident, intracranial defect (aneurysm, arteriovenous malformation, neoplasm), or severe uncontrolled arterial hypertension (SBP>180/DBP>110).  Risk versus benefit should be carefully considered in the following conditions and thrombolytic therapy administered with caution in patients with recent (10 days) serious GI bleed or recent (10 days) surgical procedure (coronary bypass graft, obstetrical delivery, organ biopsy, puncture of noncompressible vessel), left heart thrombus, subacute bacterial endocarditis, hemostatic defect, CV disease, diabetic hemorrhagic retinopathy, or pregnancy.  Clinical monitoring of hematopoietic, bleeding and coagulation functions is recommended prior to initiation of thrombolytic therapy.  Measures of fibrinolytic activity and/or coagulation functions during infusion do not correlate with efficacy or risk of bleeding.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29914, 14157, 'Urokinase', 'Liver Diseases', 'Urokinase undergoes extensive clearance and degradation by the liver.  The pharmacokinetic disposition of urokinase has not been fully determined, however it is expected that the half-life of urokinase would be prolonged in patients with hepatic impairment.  Therapy with urokinase should be administered cautiously in patients with compromised hepatic function.  Clinical monitoring of bleeding functions should be determined prior to initiation of therapy.  Measures of fibrinolytic activity and/or coagulation functions during infusion do not correlate with efficacy or risk of bleeding.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29915, 14158, 'Urokinase', 'Liver Diseases', 'Urokinase undergoes extensive clearance and degradation by the liver.  The pharmacokinetic disposition of urokinase has not been fully determined, however it is expected that the half-life of urokinase would be prolonged in patients with hepatic impairment.  Therapy with urokinase should be administered cautiously in patients with compromised hepatic function.  Clinical monitoring of bleeding functions should be determined prior to initiation of therapy.  Measures of fibrinolytic activity and/or coagulation functions during infusion do not correlate with efficacy or risk of bleeding.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29916, 14159, 'Urokinase', 'Liver Diseases', 'Urokinase undergoes extensive clearance and degradation by the liver.  The pharmacokinetic disposition of urokinase has not been fully determined, however it is expected that the half-life of urokinase would be prolonged in patients with hepatic impairment.  Therapy with urokinase should be administered cautiously in patients with compromised hepatic function.  Clinical monitoring of bleeding functions should be determined prior to initiation of therapy.  Measures of fibrinolytic activity and/or coagulation functions during infusion do not correlate with efficacy or risk of bleeding.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29917, 27493, 'Ustekinumab', 'Neoplasms', 'In clinical trials malignancies have been observed in patients receiving ustekinumab.  Patients should be monitored for non-melanoma skin cancers (NMSCs), particularly those patients who have had prior prolonged phototherapy treatment.  Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer.  Caution should be exercised when considering ustekinumab for the treatment of patients with a history of malignancy, those who have a known malignancy, or in continuing treatment in patients who develop malignancy while receiving this agent.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29918, 27494, 'Ustekinumab', 'Neoplasms', 'In clinical trials malignancies have been observed in patients receiving ustekinumab.  Patients should be monitored for non-melanoma skin cancers (NMSCs), particularly those patients who have had prior prolonged phototherapy treatment.  Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer.  Caution should be exercised when considering ustekinumab for the treatment of patients with a history of malignancy, those who have a known malignancy, or in continuing treatment in patients who develop malignancy while receiving this agent.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29919, 27495, 'Ustekinumab', 'Neoplasms', 'In clinical trials malignancies have been observed in patients receiving ustekinumab.  Patients should be monitored for non-melanoma skin cancers (NMSCs), particularly those patients who have had prior prolonged phototherapy treatment.  Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer.  Caution should be exercised when considering ustekinumab for the treatment of patients with a history of malignancy, those who have a known malignancy, or in continuing treatment in patients who develop malignancy while receiving this agent.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29920, 27493, 'Ustekinumab', 'Posterior Leukoencephalopathy Syndrome', 'The use of ustekinumab may cause posterior leukoencephalopathy syndrome.  One case of reversible posterior leukoencephalopathy syndrome (RPLS) was observed in clinical studies of psoriasis and psoriatic arthritis.  No cases of RPLS were observed in clinical studies of Crohn''s disease.  Conditions with which it has been associated include preeclampsia, eclampsia, acute hypertension, cytotoxic agents and immunosuppressive therapy.  Caution and close monitoring is advised when prescribing this agent to patients at risk of RPLS.  It is recommended to administer appropriate treatment and discontinue therapy if RPLS is suspected.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29921, 27494, 'Ustekinumab', 'Posterior Leukoencephalopathy Syndrome', 'The use of ustekinumab may cause posterior leukoencephalopathy syndrome.  One case of reversible posterior leukoencephalopathy syndrome (RPLS) was observed in clinical studies of psoriasis and psoriatic arthritis.  No cases of RPLS were observed in clinical studies of Crohn''s disease.  Conditions with which it has been associated include preeclampsia, eclampsia, acute hypertension, cytotoxic agents and immunosuppressive therapy.  Caution and close monitoring is advised when prescribing this agent to patients at risk of RPLS.  It is recommended to administer appropriate treatment and discontinue therapy if RPLS is suspected.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29922, 27495, 'Ustekinumab', 'Posterior Leukoencephalopathy Syndrome', 'The use of ustekinumab may cause posterior leukoencephalopathy syndrome.  One case of reversible posterior leukoencephalopathy syndrome (RPLS) was observed in clinical studies of psoriasis and psoriatic arthritis.  No cases of RPLS were observed in clinical studies of Crohn''s disease.  Conditions with which it has been associated include preeclampsia, eclampsia, acute hypertension, cytotoxic agents and immunosuppressive therapy.  Caution and close monitoring is advised when prescribing this agent to patients at risk of RPLS.  It is recommended to administer appropriate treatment and discontinue therapy if RPLS is suspected.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29923, 27493, 'Ustekinumab', 'Infections', 'There have been reports of serious infections, including infections with opportunistic pathogens, and reactivation of latent infections in patients receiving interleukin inhibitors.  Treatment with these agents should not be initiated in patients with an active infection until the infection resolves or is adequately treated.  Caution is recommended when considering the use of interleukin inhibitors in patients with a history of recurrent infections, underlying conditions which may predispose them to infections, or chronic, latent, or localized infections.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29924, 27494, 'Ustekinumab', 'Infections', 'There have been reports of serious infections, including infections with opportunistic pathogens, and reactivation of latent infections in patients receiving interleukin inhibitors.  Treatment with these agents should not be initiated in patients with an active infection until the infection resolves or is adequately treated.  Caution is recommended when considering the use of interleukin inhibitors in patients with a history of recurrent infections, underlying conditions which may predispose them to infections, or chronic, latent, or localized infections.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29925, 27495, 'Ustekinumab', 'Infections', 'There have been reports of serious infections, including infections with opportunistic pathogens, and reactivation of latent infections in patients receiving interleukin inhibitors.  Treatment with these agents should not be initiated in patients with an active infection until the infection resolves or is adequately treated.  Caution is recommended when considering the use of interleukin inhibitors in patients with a history of recurrent infections, underlying conditions which may predispose them to infections, or chronic, latent, or localized infections.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29926, 27493, 'Ustekinumab', 'Tuberculosis', 'Before initiating certain interleukin inhibitors, patients should be screened for latent tuberculosis infection with a tuberculin skin test.  Do not administer these agents to patients with an active tuberculosis infection.  Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy.  Anti-tuberculosis therapy should be considered prior to initiation of therapy in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29927, 27494, 'Ustekinumab', 'Tuberculosis', 'Before initiating certain interleukin inhibitors, patients should be screened for latent tuberculosis infection with a tuberculin skin test.  Do not administer these agents to patients with an active tuberculosis infection.  Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy.  Anti-tuberculosis therapy should be considered prior to initiation of therapy in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29928, 27495, 'Ustekinumab', 'Tuberculosis', 'Before initiating certain interleukin inhibitors, patients should be screened for latent tuberculosis infection with a tuberculin skin test.  Do not administer these agents to patients with an active tuberculosis infection.  Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy.  Anti-tuberculosis therapy should be considered prior to initiation of therapy in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29929, 0, 'Valaciclovir', 'Dehydration', 'Valacyclovir is almost completely converted to acyclovir and L-valine by first-pass intestinal and/or hepatic metabolism; acyclovir is primarily eliminated by the kidney.  Cases of acute renal failure have been reported in patients without adequate hydration.  Acyclovir may precipitate in renal tubules when the solubility (2.5 mg/mL) is exceeded in the intratubular fluid.  Adequate hydration should be maintained for all patients.  If acute renal failure and anuria occur, patients may benefit from hemodialysis until renal function is restored.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29930, 0, 'Valaciclovir', 'Diseases requiring hemodialysis', 'Valacyclovir is almost completely converted to acyclovir and L-valine by first-pass intestinal and/or hepatic metabolism.  About one-third of acyclovir in the body is removed by dialysis during a 4-hour hemodialysis session.  The recommended dose of valacyclovir should be administered after hemodialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29931, 0, 'Valaciclovir', 'Kidney Diseases', 'Valacyclovir is almost completely converted to acyclovir and L-valine by first-pass intestinal and/or hepatic metabolism; acyclovir is primarily eliminated by the kidney.  Cases of acute renal failure and CNS side effects (including agitation, hallucinations, confusion, delirium, seizures, and encephalopathy) have been reported in patients with preexisting renal disease who received higher-than-recommended doses of valacyclovir for their level of renal function.  Cases of acute renal failure have also been reported in patients receiving other nephrotoxic agents.  Therapy with valacyclovir should be administered cautiously in elderly patients (with or without renal dysfunction) and patients receiving other nephrotoxic agents.  Dosage reductions are recommended in patients with renal dysfunction.  If acute renal failure and anuria occur, patients may benefit from hemodialysis until renal function is restored; valacyclovir should be discontinued if CNS side effects develop.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29932, 0, 'Valaciclovir', 'Purpura, Thrombotic Thrombocytopenic', 'Thrombotic thrombocytopenic purpura/hemolytic uremia syndrome (TTP/HUS), in some cases resulting in death, has been reported in patients with advanced HIV-1 disease, in allogeneic bone marrow transplant recipients, and in renal transplant recipients during clinical trials of valacyclovir at doses of 8 g/day.  Therapy with valacyclovir should be discontinued immediately if clinical signs, symptoms, and laboratory abnormalities consistent with TTP/HUS develop.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29933, 1513, 'Ursodeoxycholic acid', 'Cholestasis', 'The use of ursodiol is contraindicated in patients with compelling reasons for cholecystectomy including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary gastrointestinal fistula.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29934, 4043, 'Ursodeoxycholic acid', 'Cholestasis', 'The use of ursodiol is contraindicated in patients with compelling reasons for cholecystectomy including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary gastrointestinal fistula.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29935, 7443, 'Ursodeoxycholic acid', 'Cholestasis', 'The use of ursodiol is contraindicated in patients with compelling reasons for cholecystectomy including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary gastrointestinal fistula.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29936, 8260, 'Ursodeoxycholic acid', 'Cholestasis', 'The use of ursodiol is contraindicated in patients with compelling reasons for cholecystectomy including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary gastrointestinal fistula.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29937, 11998, 'Ursodeoxycholic acid', 'Cholestasis', 'The use of ursodiol is contraindicated in patients with compelling reasons for cholecystectomy including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary gastrointestinal fistula.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29938, 12001, 'Ursodeoxycholic acid', 'Cholestasis', 'The use of ursodiol is contraindicated in patients with compelling reasons for cholecystectomy including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary gastrointestinal fistula.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29939, 12004, 'Ursodeoxycholic acid', 'Cholestasis', 'The use of ursodiol is contraindicated in patients with compelling reasons for cholecystectomy including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary gastrointestinal fistula.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29940, 18128, 'Ursodeoxycholic acid', 'Cholestasis', 'The use of ursodiol is contraindicated in patients with compelling reasons for cholecystectomy including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary gastrointestinal fistula.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29941, 19544, 'Ursodeoxycholic acid', 'Cholestasis', 'The use of ursodiol is contraindicated in patients with compelling reasons for cholecystectomy including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary gastrointestinal fistula.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29942, 28643, 'Ursodeoxycholic acid', 'Cholestasis', 'The use of ursodiol is contraindicated in patients with compelling reasons for cholecystectomy including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary gastrointestinal fistula.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29943, 28868, 'Ursodeoxycholic acid', 'Cholestasis', 'The use of ursodiol is contraindicated in patients with compelling reasons for cholecystectomy including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary gastrointestinal fistula.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29944, 28869, 'Ursodeoxycholic acid', 'Cholestasis', 'The use of ursodiol is contraindicated in patients with compelling reasons for cholecystectomy including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary gastrointestinal fistula.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29945, 28870, 'Ursodeoxycholic acid', 'Cholestasis', 'The use of ursodiol is contraindicated in patients with compelling reasons for cholecystectomy including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary gastrointestinal fistula.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29946, 28871, 'Ursodeoxycholic acid', 'Cholestasis', 'The use of ursodiol is contraindicated in patients with compelling reasons for cholecystectomy including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary gastrointestinal fistula.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29947, 28873, 'Ursodeoxycholic acid', 'Cholestasis', 'The use of ursodiol is contraindicated in patients with compelling reasons for cholecystectomy including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary gastrointestinal fistula.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29948, 28875, 'Ursodeoxycholic acid', 'Cholestasis', 'The use of ursodiol is contraindicated in patients with compelling reasons for cholecystectomy including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary gastrointestinal fistula.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29949, 28878, 'Ursodeoxycholic acid', 'Cholestasis', 'The use of ursodiol is contraindicated in patients with compelling reasons for cholecystectomy including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary gastrointestinal fistula.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29950, 28879, 'Ursodeoxycholic acid', 'Cholestasis', 'The use of ursodiol is contraindicated in patients with compelling reasons for cholecystectomy including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary gastrointestinal fistula.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29951, 32828, 'Ursodeoxycholic acid', 'Cholestasis', 'The use of ursodiol is contraindicated in patients with compelling reasons for cholecystectomy including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary gastrointestinal fistula.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29952, 1513, 'Ursodeoxycholic acid', 'Hepatic Insufficiency', 'Ursodiol therapy has not been associated with liver damage.  However, patients given ursodiol should have liver function tests and bilirubin levels measured at the initiation of therapy and every month for three months after start of therapy, and every six months thereafter as appropriate.  Close monitoring should be exercised in patients with liver impairment.  Treatment discontinuation should be considered if the above parameters increase to a level considered clinically significant.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29953, 4043, 'Ursodeoxycholic acid', 'Hepatic Insufficiency', 'Ursodiol therapy has not been associated with liver damage.  However, patients given ursodiol should have liver function tests and bilirubin levels measured at the initiation of therapy and every month for three months after start of therapy, and every six months thereafter as appropriate.  Close monitoring should be exercised in patients with liver impairment.  Treatment discontinuation should be considered if the above parameters increase to a level considered clinically significant.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29954, 7443, 'Ursodeoxycholic acid', 'Hepatic Insufficiency', 'Ursodiol therapy has not been associated with liver damage.  However, patients given ursodiol should have liver function tests and bilirubin levels measured at the initiation of therapy and every month for three months after start of therapy, and every six months thereafter as appropriate.  Close monitoring should be exercised in patients with liver impairment.  Treatment discontinuation should be considered if the above parameters increase to a level considered clinically significant.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29955, 8260, 'Ursodeoxycholic acid', 'Hepatic Insufficiency', 'Ursodiol therapy has not been associated with liver damage.  However, patients given ursodiol should have liver function tests and bilirubin levels measured at the initiation of therapy and every month for three months after start of therapy, and every six months thereafter as appropriate.  Close monitoring should be exercised in patients with liver impairment.  Treatment discontinuation should be considered if the above parameters increase to a level considered clinically significant.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29956, 11998, 'Ursodeoxycholic acid', 'Hepatic Insufficiency', 'Ursodiol therapy has not been associated with liver damage.  However, patients given ursodiol should have liver function tests and bilirubin levels measured at the initiation of therapy and every month for three months after start of therapy, and every six months thereafter as appropriate.  Close monitoring should be exercised in patients with liver impairment.  Treatment discontinuation should be considered if the above parameters increase to a level considered clinically significant.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29957, 12001, 'Ursodeoxycholic acid', 'Hepatic Insufficiency', 'Ursodiol therapy has not been associated with liver damage.  However, patients given ursodiol should have liver function tests and bilirubin levels measured at the initiation of therapy and every month for three months after start of therapy, and every six months thereafter as appropriate.  Close monitoring should be exercised in patients with liver impairment.  Treatment discontinuation should be considered if the above parameters increase to a level considered clinically significant.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29958, 12004, 'Ursodeoxycholic acid', 'Hepatic Insufficiency', 'Ursodiol therapy has not been associated with liver damage.  However, patients given ursodiol should have liver function tests and bilirubin levels measured at the initiation of therapy and every month for three months after start of therapy, and every six months thereafter as appropriate.  Close monitoring should be exercised in patients with liver impairment.  Treatment discontinuation should be considered if the above parameters increase to a level considered clinically significant.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29959, 18128, 'Ursodeoxycholic acid', 'Hepatic Insufficiency', 'Ursodiol therapy has not been associated with liver damage.  However, patients given ursodiol should have liver function tests and bilirubin levels measured at the initiation of therapy and every month for three months after start of therapy, and every six months thereafter as appropriate.  Close monitoring should be exercised in patients with liver impairment.  Treatment discontinuation should be considered if the above parameters increase to a level considered clinically significant.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29960, 19544, 'Ursodeoxycholic acid', 'Hepatic Insufficiency', 'Ursodiol therapy has not been associated with liver damage.  However, patients given ursodiol should have liver function tests and bilirubin levels measured at the initiation of therapy and every month for three months after start of therapy, and every six months thereafter as appropriate.  Close monitoring should be exercised in patients with liver impairment.  Treatment discontinuation should be considered if the above parameters increase to a level considered clinically significant.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29961, 28643, 'Ursodeoxycholic acid', 'Hepatic Insufficiency', 'Ursodiol therapy has not been associated with liver damage.  However, patients given ursodiol should have liver function tests and bilirubin levels measured at the initiation of therapy and every month for three months after start of therapy, and every six months thereafter as appropriate.  Close monitoring should be exercised in patients with liver impairment.  Treatment discontinuation should be considered if the above parameters increase to a level considered clinically significant.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29962, 28868, 'Ursodeoxycholic acid', 'Hepatic Insufficiency', 'Ursodiol therapy has not been associated with liver damage.  However, patients given ursodiol should have liver function tests and bilirubin levels measured at the initiation of therapy and every month for three months after start of therapy, and every six months thereafter as appropriate.  Close monitoring should be exercised in patients with liver impairment.  Treatment discontinuation should be considered if the above parameters increase to a level considered clinically significant.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29963, 28869, 'Ursodeoxycholic acid', 'Hepatic Insufficiency', 'Ursodiol therapy has not been associated with liver damage.  However, patients given ursodiol should have liver function tests and bilirubin levels measured at the initiation of therapy and every month for three months after start of therapy, and every six months thereafter as appropriate.  Close monitoring should be exercised in patients with liver impairment.  Treatment discontinuation should be considered if the above parameters increase to a level considered clinically significant.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29964, 28870, 'Ursodeoxycholic acid', 'Hepatic Insufficiency', 'Ursodiol therapy has not been associated with liver damage.  However, patients given ursodiol should have liver function tests and bilirubin levels measured at the initiation of therapy and every month for three months after start of therapy, and every six months thereafter as appropriate.  Close monitoring should be exercised in patients with liver impairment.  Treatment discontinuation should be considered if the above parameters increase to a level considered clinically significant.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29965, 28871, 'Ursodeoxycholic acid', 'Hepatic Insufficiency', 'Ursodiol therapy has not been associated with liver damage.  However, patients given ursodiol should have liver function tests and bilirubin levels measured at the initiation of therapy and every month for three months after start of therapy, and every six months thereafter as appropriate.  Close monitoring should be exercised in patients with liver impairment.  Treatment discontinuation should be considered if the above parameters increase to a level considered clinically significant.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29966, 28873, 'Ursodeoxycholic acid', 'Hepatic Insufficiency', 'Ursodiol therapy has not been associated with liver damage.  However, patients given ursodiol should have liver function tests and bilirubin levels measured at the initiation of therapy and every month for three months after start of therapy, and every six months thereafter as appropriate.  Close monitoring should be exercised in patients with liver impairment.  Treatment discontinuation should be considered if the above parameters increase to a level considered clinically significant.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29967, 28875, 'Ursodeoxycholic acid', 'Hepatic Insufficiency', 'Ursodiol therapy has not been associated with liver damage.  However, patients given ursodiol should have liver function tests and bilirubin levels measured at the initiation of therapy and every month for three months after start of therapy, and every six months thereafter as appropriate.  Close monitoring should be exercised in patients with liver impairment.  Treatment discontinuation should be considered if the above parameters increase to a level considered clinically significant.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29968, 28878, 'Ursodeoxycholic acid', 'Hepatic Insufficiency', 'Ursodiol therapy has not been associated with liver damage.  However, patients given ursodiol should have liver function tests and bilirubin levels measured at the initiation of therapy and every month for three months after start of therapy, and every six months thereafter as appropriate.  Close monitoring should be exercised in patients with liver impairment.  Treatment discontinuation should be considered if the above parameters increase to a level considered clinically significant.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29969, 28879, 'Ursodeoxycholic acid', 'Hepatic Insufficiency', 'Ursodiol therapy has not been associated with liver damage.  However, patients given ursodiol should have liver function tests and bilirubin levels measured at the initiation of therapy and every month for three months after start of therapy, and every six months thereafter as appropriate.  Close monitoring should be exercised in patients with liver impairment.  Treatment discontinuation should be considered if the above parameters increase to a level considered clinically significant.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29970, 32828, 'Ursodeoxycholic acid', 'Hepatic Insufficiency', 'Ursodiol therapy has not been associated with liver damage.  However, patients given ursodiol should have liver function tests and bilirubin levels measured at the initiation of therapy and every month for three months after start of therapy, and every six months thereafter as appropriate.  Close monitoring should be exercised in patients with liver impairment.  Treatment discontinuation should be considered if the above parameters increase to a level considered clinically significant.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29971, 0, 'Valbenazine', 'Liver Diseases', 'Valbenazine is extensively metabolized after oral administration by the liver.  Dosage adjustment of valbenazine 40 mg once daily is recommended for patients with moderate or severe hepatic impairment (Child-Pugh score 7 to 15).  Close monitoring of hepatic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29972, 0, 'Valbenazine', 'Long QT Syndrome', 'Valbenazine may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing.  The use of valbenazine should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval.  For patients at increased risk of a prolonged QT interval, it is recommended to assess the QT interval before increasing the dosage.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29973, 0, 'Valbenazine', 'Kidney Diseases', 'The use of valbenazine is not recommended in patients with severe renal impairment (creatinine clearance <30 mL/min).  Dosage adjustment is not necessary for patients with mild to moderate renal impairment (creatinine clearance 30 to 90 mL/min).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29974, 0, 'Valbenazine', 'Parkinson Disease', 'The use of vesicular monoamine transporter 2 (VMAT2) inhibitor, such as valbenazine and deutetrabenazine may cause parkinsonism in patients with tardive dyskinesia.  These agents should be used with caution in patients with parkinson disease or those presenting with parkinson-like symptoms such as, falls, gait disturbances, tremor, drooling and hypokinesia.  It is recommended to reduce the dose or to discontinue treatment in patients who develop clinically significant parkinson-like signs or symptoms while on treatment with these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29975, 0, 'Benzylpenicillin (sodium)', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29976, 0, 'Benzylpenicillin (sodium)', 'Asthma', 'Penicillin products should be used with caution in individuals with histories of significant allergies and/or asthma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29977, 18351, 'Vedolizumab', 'Infections', 'Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents.  Patients receiving immunosuppressants are at increased risk of developing bacterial, viral, fungal, and protozoal infections, and new or reactivated viral infections including opportunistic infections.  Caution should be exercised when considering their use in patients with severe or chronic infections.  It is recommended to interrupt therapy in patients who develop a new infection while undergoing treatment and to monitor these patients closely for any sign or symptom indicative of infection.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29978, 18351, 'Vedolizumab', 'Leukoencephalopathy, Progressive Multifocal', 'Immunosuppressive agents may increase the risk of progressive multifocal leukoencephalopathy (PML).  Certain agents are contraindicated in patients who have or have had PML.  Patients receiving chronic immunosuppressant or immunomodulatory therapy or who have systemic medical conditions resulting in significantly compromised immune system function should not be treated with these agents.  Healthcare professionals should monitor patients for any new sign or symptom suggestive of PML.  Withhold therapy dosing immediately and perform an appropriate diagnostic evaluation at the first sign or symptom suggestive of PML.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29979, 18351, 'Vedolizumab', 'Liver Diseases', 'Elevated transaminase levels with or without elevated bilirubin have occurred in patients who received vedolizumab.  Care should be exercised when using this agent in patients predisposed to liver injury.  Do not use vedolizumab in patients with jaundice or other evidence of significant liver injury.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29980, 0, 'Vandetanib', 'Long QT Syndrome', 'Vandetanib can prolong the QT interval, and its use is contraindicated in patients with congenital long QT syndrome.  Additionally, vandetanib should not be used in patients with hypocalcemia, hypokalemia, hypomagnesemia, or long QT syndrome.  Care should be exercised when using this agent in patients with ventricular arrhythmias or recent myocardial infarction.  It is recommended to correct hypocalcemia, hypokalemia and/or hypomagnesemia prior to starting therapy with vandetanib.  Obtain an ECG and serum potassium, calcium, magnesium and TSH at baseline, during treatment, and frequently as necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29981, 0, 'Vandetanib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29982, 0, 'Vandetanib', 'Heart Failure', 'Heart failure, including fatalities have occurred in patients treated with vandetanib.  Monitor for signs and symptoms of heart failure.  Consider discontinuation of therapy in patients with heart failure.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29983, 0, 'Vandetanib', 'Hemorrhage', 'Serious hemorrhagic events, including fatalities, have occurred in patients treated with vandetanib.  Do not administer vandetanib to patients with a recent history of hemoptysis of >= 1/2 teaspoon of red blood.  Discontinue treatment in patients with severe hemorrhage.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29984, 0, 'Vandetanib', 'Hepatic Insufficiency', 'The use of vandetanib is not recommended for patients with moderate and severe hepatic impairment, as the safety and efficacy of this agent have not been established.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29985, 0, 'Vandetanib', 'Hypertension', 'Hypertension, including hypertensive crisis, has occurred in patients treated with vandetanib.  Monitor all patients for hypertension and a dose reduction or interruption may be necessary.  If hypertension cannot be controlled, do not resume vandetanib.  Care should be taken when using this agent in hypertensive patients.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29986, 0, 'Vandetanib', 'Hypothyroidism', 'Increased dosing of thyroid replacement therapy was required in patients with a prior thyroidectomy.  It is recommended to obtain Thyroid-stimulating hormone (TSH) at baseline, during therapy and thereafter as clinically indicated.  If signs or symptoms of hypothyroidism occur, examine thyroid hormone levels and adjust thyroid replacement therapy accordingly.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29987, 0, 'Vandetanib', 'Ischemic Attack, Transient', 'Ischemic cerebrovascular events, including fatalities, occurred in patients treated with vandetanib.  The safety of resumption of vandetanib therapy after resolution of an ischemic cerebrovascular event has not been studied.  Care should be taken when prescribing this agent to patients at risk.  Discontinue treatment in patients who experience a severe ischemic cerebrovascular event.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29988, 0, 'Vandetanib', 'Kidney Diseases', 'Vandetanib exposure is increased in patients with impaired renal function.  It is recommended to reduce the starting dose in patients with moderate to severe renal impairment and monitor the QT interval closely.  There is no information available for patients with end-stage renal disease requiring dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29989, 0, 'Vandetanib', 'Posterior Leukoencephalopathy Syndrome', 'Reversible posterior leukoencephalopathy syndrome (RPLS), a syndrome of subcortical vasogenic edema diagnosed by an MRI of the brain, has occurred in patients treated with vandetanib.  Consider this syndrome in any patient presenting with seizures, headache, visual disturbances, confusion or altered mental function.  It is recommended to discontinue therapy in patients developing RPLS.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29990, 0, 'Valrubicin', 'Urinary Bladder Diseases', 'Valrubicin is contraindicated in patients with perforated bladder or compromised bladder mucosa, including small bladder capacity that is unable to tolerate a 75 mL instillation.  Evaluate the bladder before the intravesical instillation for severe irritable bladder symptoms, and in case of bladder perforation, delay the administration until bladder integrity has been restored.  If this agent is administered to patients with bladder rupture or if perforation is suspected, significant systemic exposure may occur following intravesical administration and myelosuppression is possible.  Weekly monitoring of complete blood counts should be performed for 3 weeks.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29991, 0, 'Valrubicin', 'Urinary Tract Infections', 'Valrubicin is contraindicated in patients with current urinary tract infection.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29992, 3029, 'Valproic acid', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29993, 3031, 'Valproic acid', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29994, 12047, 'Valproic acid', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29995, 12121, 'Valproic acid', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29996, 17129, 'Valproic acid', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29997, 17258, 'Valproic acid', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29998, 17262, 'Valproic acid', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29999, 17264, 'Valproic acid', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30000, 22532, 'Valproic acid', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '', 'DDInter', 0);
